International Journal of Complementary and Internal Medicine
- CASE REPORT
Progressive Evolution of Ulcerative Colitis Toward Axial Spondyloarthritis and Pyoderma Gangrenosum: Case Report and Critical Literature Review
Marco Antonio Ditta.1 Arturo Acosta Bendek.2 Angelo Arzuaga Hernandez.3 Elias Forero illera.3 María José Viera Contreras. Andrés Carrascal Ángelo.4 Rodrigo Molina Higgins.4
.1Resident Physician in Internal Medicine, Universidad Metropolitana, Barranquilla, Colombia - .2Gastroenterologist, UNIGASTRO IPS, Barranquilla, Colombia
- .3Rheumatologist, Department of Rheumatology, CIRCARIBE, Barranquilla, Colombia
- .4Internal Medicine, Universidad Simon Bolivar, Barranquilla, Colombia
Corresponding Author: Marco Antonio Ditta Cassiani. Metropolitan University, Barranquilla/Colombia Address: 76th Street No. 42-78 Garden City Neighborhood, Barranquilla, Atlantico. E-mail: [email protected]
Received: November 07, 2025 Published: November 19, 2025
Citation: Antonio Ditta CM. Progressive Evolution of Ulcerative Colitis Toward Axial Spondyloarthritis and Pyoderma Gangrenosum: Case Report and Critical Literature Review. Int J Complement Intern Med. 2025;6(4):463–468. DOI: 10. 58349/IJCIM. 4. 6. 2025. 00165
Copyright: ©2025 Antonio Ditta CM. This is an open access article distributed under the terms of the Creative Commons AttributionLicense, which permits unrestricted use, distribution, and build upon your work non-commercially.
Introduction
- Inflammatory bowel disease (IBD) is a chronic inflammatory condition of multifactorial etiology that primarily includes ulcerative colitis (UC) and Crohn’s disease (CD).1 UC affects the colonic mucosa in a continuous pattern, whereas CD is characterized by a patchy, transmural involvement that can affect any segment of the gastrointestinal tract. 1 Both entities typically follow a relapsing–remitting course and are associated with extraintestinal manifestations in up to 36% of cases, musculoskeletal involvement being the most frequent.2,3
References
1. Álvarez de Cienfuegos A, Tévar M. Inflammatory bowel disease and rheumatology. In: Sociedad Valenciana de Reumatología. Rheumatic Diseases: SVR Update 2013. Chapter 27. p. 587–594. - 2. Fernández Castro M, García Aparicio AM. Rheumatologic manifestations in inflammatory bowel disease. Iatreia. 2006;19(3):235–244.
3. Fernández Castro M, Fernández Suárez A. Extraintestinal manifestations of inflammatory bowel disease. Rev Gastroenterol Mex. 2005;70(1):47–56. 4. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20(3):451– 471. - 5. Orchard TR, Wordsworth BP. Musculoskeletal manifestations in inflammatory bowel disease. Clin Med. 2005;5(5):483–488.
- 6. Van Praet L, Van den Bosch F, Mielants H. Extra-articular manifestations of spondyloarthritis. Best Pract Res Clin Rheumatol. 2012;26(5):597–609. 7. Smith JA. Update on ankylosing spondylitis: current concepts and treatment. Rheumatology (Oxford). 2006;45(3):289–295.
- 8. Brown MA, Kenna T, Wordsworth BP. Genetics of ankylosing spondylitis. Arthritis Res Ther. 2016;18:51.
- 9. Ahmad T, Armuzzi A, Bunce M, et al. The molecular genetics of inflammatory bowel disease. Gut. 2001;48(4):571–577.
- 10. Brooklyn T, Dunnill G, Probert C. Diagnosis and treatment of pyoderma gangrenosum. BMJ. 2006;333(7560):181–184.
- 11. Reichrath J, Bens G, Bonowitz A, et al. Pyoderma gangrenosum: clinical presentation and outcome in 21 patients. J Eur Acad Dermatol Venereol. 2005;19(2):142– 148.
- 12. Alavi A, French LE, Davis MD, et al. Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol. 2017;18(3):355–372.
- 13. Ashrafi M, Flint J, Maher J, et al. Pyoderma gangrenosum: a review of clinical features and outcomes of 23 cases. Br J Dermatol. 2021;184(6):1087–1094.
- 14. Vavricka SR, Rogler G, Gantenbein C, et al. Anti-TNF treatment in patients with IBD and associated extraintestinal manifestations. Aliment Pharmacol Ther. 2012;36(4):372– 383.
- 15. Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis. Part 3: Special situations. J Crohns Colitis. 2013;7(1):1–33.
- 16. Sands BE, Peyrin-Biroulet L, Loftus EV Jr, et al. Vedolizumab versus adalimumab for moderate-to-severe ulcerative colitis. N Engl J Med. 2019;381(13):1215–1226.
- 17. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549.
- 18. Alvarado JA, Bustamante E, Rodríguez G, et al. Pyoderma gangrenosum in inflammatory bowel disease: response to infliximab. Rev Col Gastroenterol. 2021;36(1):65–71.
- 19. Ruiz-Morales M, Román-Murguía M, Ruiz-Baca E, et al. Cutaneous and articular response to infliximab in ulcerative colitis complicated with pyoderma gangrenosum. Med Clin (Barc). 2017;148(5):227–229.
- 20. Bertoló MS, Ruiz M, Contreras C. Pyoderma gangrenosum: excellent response to combined topical therapy. Rev Med Chil. 2015;143(11):130–2.
- 21. González C, Mendoza JL, Taxonera C, et al. Articular manifestations of inflammatory bowel disease: experience in 215 patients. Med Clin (Barc). 2003;121(12):441–444.
.png)
